High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsPodoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation.Leptomeningeal disease: current diagnostic and therapeutic strategies.In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review.Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms.Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.
P2860
Q26740529-266C2494-74A3-4980-AEDD-4EEE965DEC16Q26741320-BB7164D2-2CF0-410C-8CFB-BC7BA3D0A246Q33607564-373F46D3-24BE-4DA9-9959-A1377684EE8BQ37646729-704FA76B-5601-4D32-8AEE-5085EE77B131Q37731945-5BEE0FC0-9E35-4547-A0DF-262F4DAD7468Q38809939-F67617BC-F7B3-4C55-9068-0E601F6B8D73Q42668078-C489B704-9303-449B-AE31-39F685851AEDQ42700664-04DCE7A0-9E06-4AAD-9C30-292BB9B25697Q47136514-6928D82C-1C73-416A-9AA2-6FA9C48C4D56Q47390697-F7F61834-A26F-4E43-9CF1-E9F72F631F8CQ47838653-B225A999-4940-4F22-908D-AD0D04DC3B92Q49894049-1F3F3551-F4CC-474C-A509-98B8255EF7C6Q54989107-52F4F752-743E-4D0B-9F5D-C3B50F8ACBE3
P2860
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High efficacy of third generat ...... EGFR-mutant lung cancer cells
@en
type
label
High efficacy of third generat ...... EGFR-mutant lung cancer cells
@en
prefLabel
High efficacy of third generat ...... EGFR-mutant lung cancer cells
@en
P2093
P2860
P50
P356
P1433
P1476
High efficacy of third generat ...... EGFR-mutant lung cancer cells
@en
P2093
Mitsutoshi Nakada
Sachiko Arai
Satsuki Mochizuki
Seiji Yano
Shigeki Nanjo
Shinji Takeuchi
Takashi Murakami
P2860
P304
P356
10.18632/ONCOTARGET.6758
P407
P577
2015-12-24T00:00:00Z